273 related articles for article (PubMed ID: 31163298)
1. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
Pinto MV; Pinto LF; Dias M; Rosa RS; Mundayat R; Pedrosa RC; Waddington-Cruz M
J Neurol Sci; 2019 Aug; 403():1-6. PubMed ID: 31163298
[TBL] [Abstract][Full Text] [Related]
2. Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis.
Zampino S; Sheikh FH; Vaishnav J; Judge D; Pan B; Daniel A; Brown E; Ebenezer G; Polydefkis M
Neurology; 2023 May; 100(19):e2036-e2044. PubMed ID: 36941075
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Waddington-Cruz M; Wixner J; Amass L; Kiszko J; Chapman D; Ando Y;
Neurol Ther; 2021 Dec; 10(2):753-766. PubMed ID: 34024024
[TBL] [Abstract][Full Text] [Related]
4. Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country.
Koutsis G; Kastritis E; Kontogeorgiou Z; Kartanou C; Kokotis P; Rentzos M; Breza M; Kleopa KA; Christodoulou K; Oikonomou E; Anastasakis A; Angelidakis P; Sarmas I; Kargiotis O; Tzagournissakis M; Zaganas I; Foukarakis E; Sachpekidis V; Papathoma A; Panas M; Stefanis L; Dimopoulos MA; Karadima G
Neuromuscul Disord; 2021 Dec; 31(12):1251-1258. PubMed ID: 34740514
[TBL] [Abstract][Full Text] [Related]
5. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile L; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Kristen A; Wixner J; Diemberger I; Gonzalez-Moreno J; Cariou E; Maurer MS; Planté-Bordeneuve V; Garcia-Pavia P; Tournev I; Gonzalez-Costello J; Duarte AG; Grogan M; Mazzeo A; Chapman D; Gupta P; Glass O; Amass L;
Orphanet J Rare Dis; 2023 Nov; 18(1):350. PubMed ID: 37946256
[TBL] [Abstract][Full Text] [Related]
6. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
7. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile L; Diemberger I; Plante-Bordeneuve V; Mazzeo A; Dori A; Luigetti M; Di Paolantonio A; Dispenzieri A; Grogan M; Waddington Cruz M; Adams D; Inamo J; Kristen AV; Lino Cirami C; Chapman D; Gupta P; Glass O; Amass L
PLoS One; 2024; 19(1):e0292435. PubMed ID: 38241252
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Barroso FA; Coelho T; Dispenzieri A; Conceição I; Waddington-Cruz M; Wixner J; Maurer MS; Rapezzi C; Planté-Bordeneuve V; Kristen AV; González-Duarte A; Chapman D; Stewart M; Amass L;
Amyloid; 2022 Sep; 29(3):175-183. PubMed ID: 35451899
[TBL] [Abstract][Full Text] [Related]
10. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y
J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547
[TBL] [Abstract][Full Text] [Related]
11. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
[TBL] [Abstract][Full Text] [Related]
12. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
Adams D; Ando Y; Beirão JM; Coelho T; Gertz MA; Gillmore JD; Hawkins PN; Lousada I; Suhr OB; Merlini G
J Neurol; 2021 Jun; 268(6):2109-2122. PubMed ID: 31907599
[TBL] [Abstract][Full Text] [Related]
13. Nerve ultrasonography findings as possible pitfall in differential diagnosis between hereditary transthyretin amyloidosis with polyneuropathy and chronic inflammatory demyelinating polyneuropathy.
Leonardi L; Vanoli F; Fionda L; Loreti S; Garibaldi M; Morino S; Salvetti M; Russo D; Musumeci B; Antonini G
Neurol Sci; 2020 Dec; 41(12):3775-3778. PubMed ID: 32936357
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
15. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS).
Cruz MW; Pinto MV; Pinto LF; Gervais R; Dias M; Perez C; Mundayat R; Ong ML; Pedrosa RC; Foguel D
Arq Neuropsiquiatr; 2019 Feb; 77(2):96-100. PubMed ID: 30810593
[TBL] [Abstract][Full Text] [Related]
16. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Waddington-Cruz M; Ando Y; Amass L; Kiszko J; Chapman D; Sekijima Y;
J Peripher Nerv Syst; 2021 Jun; 26(2):160-166. PubMed ID: 33844361
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey.
González-Moreno J; Dispenzieri A; Grogan M; Coelho T; Tournev I; Waddington-Cruz M; Wixner J; Diemberger I; Garcia-Pavia P; Chapman D; Gupta P; Glass O; Amass L;
Cardiol Ther; 2024 Mar; 13(1):117-135. PubMed ID: 38117424
[TBL] [Abstract][Full Text] [Related]
19. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
20. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.
Lin X; Yarlas A; Vera-Llonch M; Baranwal N; Biber J; Brown D; Vogt B; Karam C
BMC Neurol; 2021 Feb; 21(1):70. PubMed ID: 33579211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
